Research programme: HuMax-ZP3 antibodies - GenmabAlternative Names: HuHax-ZP3
Latest Information Update: 10 Oct 2008
At a glance
- Originator Genmab
- Class Antibodies
- Mechanism of Action Immunostimulants; Natural killer cell stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 10 Oct 2008 Discontinued - Preclinical for Solid tumours in Denmark (unspecified route)
- 13 Dec 2006 Preclinical trials in Solid tumours in Denmark (unspecified route)